文献速递MDS 与骨髓增殖性肿瘤

靶向核输出与JAK/STAT信号通路治疗骨髓纤维化的新型联合策略

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.
PubMed 文献 · Br J Haematol · 2026-07-14

骨髓纤维化(MF)中JAK2抑制剂如芦可替尼疗效有限且易耐药。本研究在JAK2V617F或CALR exon 9突变MPN细胞系及MF患者样本中评估塞利尼索联合芦可替尼,发现联合方案抗增殖活性优于单药,可抑制MF CD34+细胞集落形成,并在芦可替尼耐药细胞中诱导G1期阻滞和凋亡。多组学分析显示联合治疗增加p53核滞留、破坏NF-κB和JAK/STAT信号,并减少MF患者PBMC分泌TNFα、IL-6和MCP-1,提示该联合策略同时影响MF造血细胞内在和微环境相关通路。

要点

  • 塞利尼索联合芦可替尼在MF模型中抗增殖活性优于单用JAK2抑制剂。
  • 联合方案抑制MF CD34+细胞集落形成,并在芦可替尼耐药细胞中诱导G1阻滞和凋亡。
  • 联合治疗增加p53核滞留、破坏NF-κB和JAK/STAT信号,减少炎症因子分泌。

核心结论

  • 塞利尼索联合芦可替尼同时作用于MF造血细胞内在和微环境相关通路,提供了一种潜在改善临床结局的新型疾病修饰策略。

研究设计与样本

  • 在JAK2V617F或CALR exon 9突变MPN细胞系及MF患者样本中评估塞利尼索联合芦可替尼的体外效果。

主要发现

  • 联合方案抗增殖活性优于单用JAK2抑制剂,并抑制MF CD34+细胞集落形成。
  • 塞利尼索在芦可替尼耐药MPN细胞系中仍有活性,诱导G1期阻滞和凋亡。
  • 多组学分析显示联合治疗增加p53核滞留,破坏NF-κB和JAK/STAT信号。
  • 联合治疗抑制NF-κB转录活性,减少MF患者外周血单个核细胞分泌TNFα、IL-6和MCP-1。

临床怎么用

  • 该联合策略尚处于临床前研究阶段,需进一步临床试验验证其疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, marrow fibrosis, cytopenias and inflammation. Janus kinase 2 (JAK2) inhibitors, such as ruxolitinib, reduce splenomegaly and alleviate symptoms but have limited disease-modifying activity, and resistance frequently develops. Selinexor, an oral selective exportin (XPO1) inhibitor, restores nuclear retention of tumour suppressors and inhibitors of inflammatory signalling. Dual XPO1/JAK2 inhibition targets complementary downstream pathways, enhancing suppression of MF progenitor cell fitness. We evaluated selinexor plus ruxolitinib in MF models, including JAK2V617F or calreticulin (CALR) exon 9-mutant MPN cell lines and samples from patients with MF. The combination showed greater anti-proliferative activity than JAK2 inhibition alone and suppressed colony formation from MF Cluster of Differentiation 34 (CD34)+ cells. Selinexor remained active in a ruxolitinib-resistant MPN cell line, inducing G1 arrest and apoptosis. Multi-omic analyses demonstrated increased nuclear retention of p53 and disruption of Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling, complementing and extending ruxolitinib-targeted pathways. The combination suppressed NF-κB transcriptional activity and reduced Tumor Necrosis Factor alpha (TNFα), Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) secretion from MF patient peripheral blood mononuclear cells. These findings highlight that selinexor plus ruxolitinib affects both MF haematopoietic cell-intrinsic and microenvironment-related pathways, providing a novel disease-modifying strategy with the potential to improve clinical outcomes in patients with MF.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kashyap T, Ellero AA, Walker CJ, et al. Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways. Br J Haematol. 2026. PMID: 42448318. doi:10.1111/bjh.70639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。